UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

VizWiz Grand Challenge: Answering Visual Questions from Blind People

2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition, 2018, p.3608-3617

2018

Volltextzugriff (PDF)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1569-1578

2020

Volltextzugriff (PDF)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The Lancet (British edition), 2020-08, Vol.396 (10249), p.467-478

2020

Volltextzugriff (PDF)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

The Lancet (British edition), 2020-12, Vol.396 (10267), p.1979-1993

2020

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

The Lancet (British edition), 2020-12, Vol.396 (10265), p.1817-1828

2020

Volltextzugriff (PDF)

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Nature medicine, 2021-10, Vol.27 (10), p.1752-1760

2021

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

The Lancet infectious diseases, 2021-02, Vol.21 (2), p.181-192

2021

Volltextzugriff (PDF)

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

The Lancet (British edition), 2021-07, Vol.398 (10296), p.213-222

2021

Volltextzugriff (PDF)

t.b.c._Kolonialzeitliche Kunst in symmetrischer Perspektive: Julius Lips und die Inversion des Blicks

Brus, Anna

1, 2025

Volltextzugriff (PDF)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

The Lancet infectious diseases, 2021-01, Vol.21 (1), p.39-51

2021

Volltextzugriff (PDF)

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2020-08, Vol.396 (10249), p.479-488

2020

Volltextzugriff (PDF)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

The Lancet (British edition), 2019-07, Vol.394 (10193), p.121-130

2019

Volltextzugriff (PDF)

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2020-10, Vol.396 (10257), p.1090-1100

2020

Volltextzugriff (PDF)

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

The Lancet (British edition), 2021-03, Vol.397 (10278), p.971-984

2021

Volltextzugriff (PDF)

Kontinuierliche Verbesserung von Organisationen: verfahrenstechnischer und kultureller Ansatz: Ein maschinell generierter Forschungsüberblick

Sawant, Madhav

2024th edition, 2024

Volltextzugriff (PDF)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-06, Vol.401 (10391), p.1853-1865

2023

Volltextzugriff (PDF)

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2020-01, Vol.21 (1), p.44-59

2020

Volltextzugriff (PDF)

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

The Lancet (British edition), 2019-11, Vol.394 (10209), p.1638-1650

2019

Volltextzugriff (PDF)

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2020-09, Vol.396 (10253), p.759-769

2020

Volltextzugriff (PDF)

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

The Lancet (British edition), 2022-04, Vol.399 (10333), p.1383-1390

2022

Volltextzugriff (PDF)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2021-07, Vol.398 (10295), p.143-155

2021

Volltextzugriff (PDF)

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1940-1948

2019

Volltextzugriff (PDF)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

The New England journal of medicine, 2021-11, Vol.385 (19), p.1774-1785

2021

Volltextzugriff (PDF)

1 – 25 von 7.610.819

Suche als RSS-Feed

Aktive Filter

KollektionJstor Complete Legacy

KollektionSpringerLink

SpracheSpanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.519.660)
Mit Volltextzugriff
(5.521.793)

Publikationsform

Artikel
(4.314.602)
Buchkapitel
(817.696)
Zeitungsartikel
(750.615)
magazinearticle
(580.527)
Dissertationen
(480.924)
Newsletter-Artikel
(225.021)
Reviews
(220.486)
Tagungsberichte
(92.078)
Bücher
(62.557)
Texte
(27.528)
Referenzeintrag
(21.684)
Berichte
(15.821)
Webseiten
(692)
Datensätze
(402)
government_documents
(49)
videos
(43)
Zeitschriften
(32)
Bilder
(15)
Sonstige
(14)
market_researchs
(12)

15 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(7.066.531)
Deutsch
(484.499)
Französisch
(31.593)
Portugiesisch
(28.185)
Japanisch
(25.601)
Polnisch
(19.614)
Niederländisch
(18.723)
Norwegisch
(15.830)
Italienisch
(9.726)
Russisch
(8.585)
Chinesisch
(7.736)
Croatian
(6.637)
Dänisch
(6.327)
Türkisch
(6.241)
Serbian
(5.593)
Slowenisch
(4.490)
Tschechisch
(3.972)
Bokmål, Norwegian; Norwegian Bokmål
(3.755)
Slowakisch
(2.739)
Koreanisch
(2.671)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.368.637)
Life Sciences & Biomedicine
(1.880.546)
Humans
(1.277.189)
Female
(722.288)
Male
(718.748)
Adult
(434.902)
Biological And Medical Sciences
(403.941)
Middle Aged
(402.915)
Social Sciences
(384.130)
Animals
(369.281)
Medical Sciences
(319.070)
Technology
(305.769)
Aged
(291.793)
Physical Sciences
(276.684)
Neurosciences & Neurology
(233.820)
Neurosciences
(194.086)
Patients
(179.096)
Treatment Outcome
(164.568)
Psychology
(159.600)
Adolescent
(156.879)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.683.700)
Ingenta
(1.670.681)
MEDLINE
(1.565.486)
Nexis Uni
(1.427.360)
Journals@Ovid Complete
(1.105.182)
Single Journals
(998.567)
IngentaConnect Journals
(837.076)
Ebook Central Perpetual and DDA
(707.076)
Wiley Online Library Journals Frontfile Complete
(693.790)
eBooks on EBSCOhost
(680.550)
Elsevier ScienceDirect Journals
(601.283)
Wiley Online Library Full Collection 2018
(522.102)
ProQuest Dissertations & Theses A&I
(480.415)
EBSCOhost Business Source Ultimate
(426.774)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(395.137)
Taylor & Francis Journals
(298.731)
Taylor & Francis Current Content Access
(290.048)
Taylor & Francis:Master (3349 titles)
(284.638)
SAGE Complete
(231.677)
Taylor & Francis eBooks A-Z
(184.283)
JSTOR
(0)
Springer Nature - Complete Springer Journals
(0)

17 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

New York Times
(126.944)
Daily Mail
(80.840)
The New York Times
(75.573)
Pr Newswire
(73.379)
Plos One
(59.972)
The Spectator
(56.868)
Times
(55.627)
Billboard
(54.181)
The Guardian
(46.646)
Daily Telegraph
(44.203)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

VizWiz Grand Challenge: Answering Visual Questions from Blind People

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

t.b.c._Kolonialzeitliche Kunst in symmetrischer Perspektive: Julius Lips und die Inversion des Blicks

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Kontinuierliche Verbesserung von Organisationen: verfahrenstechnischer und kultureller Ansatz: Ein maschinell generierter Forschungsüberblick

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

Aktive Filter

Suchergebnisse filtern